KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Liabilities: 2016-2024

Historic Total Liabilities for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to $3.2 billion.

  • Moderna's Total Liabilities fell 27.63% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 27.63%. This contributed to the annual value of $3.2 billion for FY2024, which is 29.11% down from last year.
  • Latest data reveals that Moderna reported Total Liabilities of $3.2 billion as of FY2024, which was down 29.11% from $4.6 billion recorded in FY2023.
  • Moderna's 5-year Total Liabilities high stood at $10.5 billion for FY2021, and its period low was $3.2 billion during FY2024.
  • In the last 3 years, Moderna's Total Liabilities had a median value of $4.6 billion in 2023 and averaged $4.8 billion.
  • Per our database at Business Quant, Moderna's Total Liabilities surged by 1,051.92% in 2020 and then plummeted by 36.00% in 2022.
  • Moderna's Total Liabilities (Yearly) stood at $4.8 billion in 2020, then skyrocketed by 120.35% to $10.5 billion in 2021, then slumped by 36.00% to $6.7 billion in 2022, then slumped by 32.12% to $4.6 billion in 2023, then declined by 29.11% to $3.2 billion in 2024.